NewsBenzingaMorgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70 Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70 Benzinga 2026.10.02 09:34 (GMT+0) Open on Benzinga Other news AI Sector Pressure, Earnings and Other Key Things to Watch this Week Disney agrees to hire the majority of Character.AI’s workforce Dividend Announcements: October 10-16, 2026 30 Dividend Buys You Might Hold Forever From October’s Russell 3000 Index TechCrunch Mobility: Rivian’s next act TSMC: The Easy Money Is Gone (NYSE:TSM)
